MedTrace Logo

Cancer Panel From Blood of Lung Cancer Patients

NCT03235765 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-01-22

No results posted yet for this study

Summary

Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. This study is aimed to to compare concordance rate between tissue based cancer panel analysis and blood based cancer panel analysis in lung cancer patients (both by NGS technique).

Conditions

  • Non Small Cell Lung Cancer Metastatic
  • Non Small Cell Lung Cancer Recurrent

Interventions

DIAGNOSTIC_TEST

MACROGEN Pan Cancer Panel (Tier 2)

This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.

Sponsors & Collaborators

  • MACROGEN

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-10
Primary Completion
2019-03-10
Completion
2020-03-10

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03235765 on ClinicalTrials.gov